- Corell-Escuin, Paula
- Belmonte-Ballester, Sonia
- Adhav, Anmol
- Marina, Alberto
- Gadea-Salom, Laura
- Martínez-Gil, Luis
- Aledavood, Elnaz
- Fernández-Escamilla, Ana María
- Gómez Sáez, Ana
- Gougeard, Nadine
- Dee, Kieran
- Murcia, Pablo R.
- Magos, Eliza Adriana
- Llena, Carmen
- Peris-Martínez, Cristina
- D'Auria, Giuseppe
- Artacho, Alejandro
- Mengual-Chulia, Beatriz
- López-Labrador, F. Xavier
- Mira, Alex
- Ferrer, Maria Desamparados
10 páginas, 5 figuras, Despite the high incidence of influenza virus infections, one-fifth of people infected with influenza remain asymptomatic. The mechanisms associated with this immune resilience are, however, unknown. Here, we show that the human antimicrobial peptide dermcidin has antiviral activity against influenza viruses through binding to hemagglutinin and extends its effect to taxonomically unrelated respiratory viruses such as measles virus and human coronavirus OC43. We show that dermcidin is present in all anatomical regions associated with the entry routes of respiratory viruses, that its levels increase during viral respiratory infections, and that it protects mice against influenza disease. Notably, dermcidin levels were higher in asymptomatic individuals than in susceptible peers, suggesting a role in the onset of disease symptoms. Thus, we show that dermcidin inhibits influenza virus infection in vitro and in vivo, with potential as a human-derived product for the prevention and treatment of respiratory viral infections., This study was supported by grants INNVAL20/19/006 and INNVA2/2021/3 from the Valencian Innovation Agency (AVI), FISABIO Innovation grant PAPIRO UGP-21-047, an EXPLORA Action from the Spanish Ministry of Science and Innovation with code SAF2013-505553-EXP, CIPROM/2023/30 from Regional Ministry of Education, Culture, Universities, and Employment of the Valencian Government, PID2022-137201NB-I00 from the Spanish Ministry of Science and Innovation and by the Carlos III Health Institute, under file code CP22/00036, pursuant to the Resolution of the Director of the Carlos III Health Institute, O.A., M.P., dated December 7, 2022, granting the Miguel Servet Contracts, and cofinanced by the European Union. We thank the patients and the IBSP-CV Biobank (PT17/0015/0017) integrated in the Spanish National Biobanks Network and in the Valencian Biobanking Network for collaboration. We also thank the Central Service for Experimental Research of Universitat de València for the sequencing. Finally, we express our gratitude to Dr. Elena Tapia, Eduardo Romanos, Dr. Julián Pardo, and Dr. Maykel Arias from Instituto Aragonés de Ciencias de la Salud for assistance with the animal experiments, to Dr. Florian Krammer for kindly providing baculoviruses expressing PR8 HA ectodomain, Dr. Jeronimo Bravo for sharing insect High Five cells and to Kenneth McCreath for helpful comments on the manuscript. E.A. and A.M.F.-E. thank Dr. Carmen Gil and Dr. Ana Martínez for valuable advice and for providing access to computational resources. Some of the figure graphics were created by using BioRender.com., Peer reviewed